Vaccine CDMO Services

Vaccine CDMO Services (mRNA, Recombinant & Viral Platforms)

Elise Biopharma runs vaccine programs as engineered systems that convert immunology into manufacturability. We start with the clinical intent—route, target population, dosing schedule, immune correlates—and translate it into a control strategy that binds antigen or genetic payload quality to process parameters you can defend at audit. Our Vaccine CDMO Services integrate antigen design or sequence selection, plasmid or template supply, upstream production (IVT, microbial, mammalian, or vector amplification), orthogonal purification, adjuvant or LNP integration, aseptic fill–finish, and a regulatory narrative that shortens review. Execution is grounded in a unified digital QMS (ALCOA+ eBR/MES; 21 CFR Part 11), with digital twins and PAT controlling the physics—mixing, mass transfer, particle formation, emulsion droplet size—so lots behave at 2 L the way they behave at 2 000 L. The result is a vaccine file that reads like engineering and ships like operations.

We cover the modalities that matter now and will matter next: mRNA/saRNA vaccines in LNPs, recombinant protein subunits and VLPs made in microbial, yeast, or mammalian systems, glycoconjugate vaccines developed in concert with our Carbohydrate platform, and viral-vectored vaccines (adenoviral, MVA, and other replication-defective platforms) under BSL-2 with partner escalation for BSL-3 where warranted. Each pathway is mapped from QTPP to CQA to CPP, then locked with compact DoE and edge-of-failure runs so ranges survive scale, raw-material drift, and site moves. We write the comparability plans you will need before you need them. We price decisions before they become surprises.

Program architecture

A vaccine succeeds when the immunobiology and the manufacturing physics keep each other honest. We begin with a QTPP that names the reality in a patient: dose, route (IM, SC, intranasal, ocular, inhaled), presentation (vial or PFS), cold-chain constraints, and immune correlates (neutralization titer, opsonophagocytic activity, T-cell profiles). CQAs follow: identity and integrity of the antigen or genetic payload, potency as measured by a clinically relevant assay, purity and residuals appropriate to route and age group, particle or droplet attributes where delivery is particulate or emulsive, sterility and endotoxin limits, and stability windows clinics can execute. CPPs then fall into place: for mRNA—IVT conditions, impurity formation control, LNP FRR/TFR/temperature; for recombinant proteins—expression temperature/pH/feed, capture and polishing windows, adjuvant mixing; for conjugates—polysaccharide chain length, activation chemistry, protein loading, free saccharide control; for vectors—MOI or transfection ratios, harvest timing, density or affinity strategies for empty/full (where applicable).

We do not bury risk in appendices. Edge-of-failure data, pooling rules, particle or droplet control recipes, and in-use handling policies are written from the clinic backward and validated in development. When your sponsor team or a reviewer wants to know “why that setpoint,” the answer is in the dossier.

mRNA / saRNA vaccines

We run the continuum—plasmid → IVT → LNP → aseptic fill-finish—under one quality system. Plasmid DNA is supplied as IVT-grade or DMF-referenced therapeutic grade with supercoiled% and endotoxin limits tuned for transcription and LNP tolerability. IVT chemistry is controlled for NTP consumption, Mg²⁺ balance, pyrophosphate handling, and dsRNA suppression; capping (CleanCap-compatible or enzymatic) is validated at scale; poly(A) size is measured with CE. Purification trains remove template DNA and protein residuals, deplete dsRNA with orthogonal confirmation, and condition the pool for LNP mixing.

Microfluidic LNP formation is run inside a narrow window—size 60–85 nm, PDI ≤ 0.05, EE ≥ 90–95%—maintained by FRR/TFR and temperature corridors, with inline DLS cross-checked by offline EM on cadence. Ionizable and helper lipids are qualified with Type IV DMFs when warranted; PEG-lipids and composition are certified per lot. Lyophilized options are developed where logistics demand it, with DSC/Tg′-informed cycles and reconstitution performance validated to “no size creep” and potency ≥0.9× fresh. Fill-finish runs in ISO 5 isolators, nitrogen overlay, 100% in-line weight checks, and CCIT. Stability spans −80/−20/2–8 °C and clinic-realistic in-use windows, with freeze–thaw policies that technicians can execute without guessing.

Analytics for mRNA/saRNA vaccines include identity and length distribution, capping efficiency, dsRNA by two methods, residuals (DNA, protein, solvents), particle attributes, potency in relevant cells, and innate-response markers where dose or route argues for them. The release panel is phase-appropriate; method lifecycle follows ICH Q2(R2) with system suitability and bracketing so day-to-day numbers have meaning.

Recombinant protein subunits and VLPs

For subunit vaccines—RBDs, HA, HBV surface antigens, toxoids—and VLPs, we use microbial (E. coli), yeast (Pichia pastoris, Saccharomyces), and mammalian (CHO/HEK) platforms as the antigen demands. Expression design is manufacturability-first: signal peptides for secretion, fusion tags only where justified and removable, glycoform control when immunogenicity or PK demands it. Upstream is driven by μ and oxygen/heat budgets, not by calendars; temperature and pH ramps protect folding; secretion and protease risk are managed as design points. Downstream capture exploits orthogonality—affinity where it pays its way, AEX/CEX/HIC as needed—to separate product from wall debris, proteolyzed fragments, and aggregates; VLPs receive size-aware clarification, TFF strategies that protect integrity, and gradients or chromatography that resolve empty/full or assembly states when they matter.

Adjuvant integration is treated as engineering, not art. For alum, we control antigen adsorption isotherms and mixing energy; for squalene emulsions, we fix droplet size and distribution and qualify droplet stability; for saponin or liposomal systems, we validate QS-like or phospholipid content and particle attributes. Presentation, preservative policy (where permitted), and container choice are defined by route and target population; residual adjuvant metrics are part of release where appropriate.

Analytics for protein/VLP vaccines include identity (intact mass, peptide mapping), aggregation (SEC-MALS), potency (ELISA antigen content, pseudovirus neutralization, HAI for influenza, cell-based function), glycoform spectra where relevant (HILIC-UPLC-MS), residual DNA/protein, endotoxin, and adjuvant-specific attributes (droplet size, zeta potential, QS-like content). Stability covers real-time and accelerated with stress panels (freeze–thaw, agitation, light) that mimic distribution and clinic, not just storage.

Glycoconjugate vaccines (with Carbohydrate platform integration)

Conjugates succeed when three variables are explicit: polysaccharide chain length, degree of activation, and protein loading. We exploit our Carbohydrate CDMO platform to synthesize or refine polysaccharides, control O-acetylation and chain length distributions, and execute activation chemistries with measurable substitution (e.g., CDAP, reductive amination, click) while limiting depolymerization. Carrier proteins (CRM197, TT, KLH, recombinant carriers) are qualified with identity and impurity maps; conjugation proceeds in buffers and ratios that achieve target degree of substitution without sacrificing epitope integrity.

Clarification and polishing remove free saccharide and unconjugated protein; free saccharide is measured by validated HPAEC-PAD or derivatization/HPLC; O-acetylation is tracked as a stability CQA when it matters to immune recognition. Formulation accounts for preservative rules in multi-dose vials; alum adsorption or emulsion integration is validated with adsorption isotherms and droplet or particle attributes. Aseptic fill-finish, CCIT, and cold chain follow the same discipline as other modalities.

Analytics: chain length, O-acetylation, degree of substitution, identity/purity of carrier, free saccharide, residual reagents, potency (opsonophagocytic activity or antigen-specific ELISAs), sterility and endotoxin, stability including real-time degradation mechanisms relevant to polysaccharide chemistry. We do not pretend a conjugate is “just a protein.” The file reads accordingly.

Viral-vectored vaccines

Replication-defective adenoviral, MVA, and analogous vectors are managed as vector programs with vaccine-specific analytics. Suspension HEK293 or producer lines are tuned for MOI, infection timing, and viability; harvest is triggered by vg productivity and cell integrity, not calendars. Downstream strategies remove host DNA and protein, enrich for active particles, and (when applicable) resolve empty/full. Formulation emphasizes cryostability and dose presentation; multi-dose policies respect preservative constraints and particle stability.

Analytics: vg titer by ddPCR, infectivity, identity (peptide mapping, genome checks), residuals, potency in cell-based transduction readouts tied to antigen expression, stability with freeze–thaw and in-use windows.

Adjuvants and delivery—catalog of control recipes

We maintain control recipes for common adjuvant classes and delivery systems:

• Alum (AIPO₄/AIO(OH)): adsorption curves, pH windows, mixing energy, desorption testing, and preservative compatibility.
• Squalene emulsions: droplet size distributions (DLS), surfactant ratios, shear regimes, and temperature holds with droplet stability thresholds; CCIT impact.
• Toll-like receptor agonists (CpG-like, MPL-like): content and impurity profiles, adsorption or encapsulation behavior, release conditions.
• Liposomal systems: lipid composition/ratios, particle size and zeta potential, stability on storage and after draw-up.
• LNP for RNA: covered above; composition and particle CQAs are treated as drug-product CQAs.

Adjuvant choices are justified by immunobiology and logistics, not fashion. We document why an emulsion droplet size matters to depot and reactogenicity, why a particular alum surface chemistry matters to antigen orientation, and why a liposomal composition matches the desired Th1/Th2 balance. Those arguments go into Module 3 so reviewers do not have to infer intent.

Potency and immunogenicity—assays reviewers trust

Potency cannot be a proxy; we design assays that reflect mechanism while remaining robust. For neutralization-driven vaccines, pseudovirus neutralization or classical PRNT (where BSL allows) are referenced to a lab standard and controlled for lot-to-lot comparability. For HA-based influenza, HAI and microneutralization are paired. For polysaccharide and conjugates, opsonophagocytic activity and antigen-specific ELISA with reference panels establish dose–response. For T-cell-oriented vaccines, ELISpot/ICS panels are developed as characterization and clinical correlative tools.

We do not pad files with vanity assays; we choose an anchored set that can be validated, transferred, and defended. That pragmatism speeds review.

Digital twins, PAT, and data integrity

Particle formation and emulsification are physical phenomena with tractable models. Our twins combine mechanistic balances (mixing, shear, heat, solvent removal) with learned shells trained on campaign data. Inline DLS, off-gas, Raman/FTIR, and historian tags feed controllers that keep LNP size and emulsions inside proven ranges. Chromatography cycles are monitored by pressure/UV/conductivity signatures to forecast breakthrough and capacity loss. eBR/MES records not just setpoints but reasons—what uncertainty the controller assumed and why. When residuals drift, alarms fire on model residuals before release assays do. Digital here is a quality tool, not a brochure line.

Regulatory and CMC posture

We write vaccine CMC like we mean to be inspected. QTPP → CQA maps name potency, purity, particle/droplet attributes, and stability windows that map to clinic; CPP ranges are set by compact DoE and edge-of-failure runs; validation and PPQ plans are explicit; and comparability scaffolds under ICH Q5E cover the changes you will make—strain drift or antigen edits, lipid lot or composition changes, adjuvant component shifts, site moves, and presentation tweaks. Method lifecycle follows ICH Q2(R2) with system suitability; viral safety and cell substrate risks align with ICH Q5A; bank narratives trace to ICH Q5D; lifecycle hooks reference ICH Q12 so expected changes ride on pre-agreed tracks. For global programs, we write to FDA CBER and EMA expectations and prepare for WHO prequalification dossiers when LMIC supply is part of the plan.

Lot release philosophies, reference standards, and stability commitments are spelled out so agencies spend time on benefit–risk, not on deciphering CMC.

Cost and throughput—pricing the levers that move COGS

We model what actually drives vaccine economics: antigen yield per reactor hour, resin and filter lifetimes under real antifoam and fouling, lipid and adjuvant costs and waste, FRR/TFR windows that minimize chip count and solvent use, multi-dose vs. single-dose presentation trade-offs, lyophilization cycle times, and cold-chain intensity. Overall equipment effectiveness is tracked for reactors, TFF, microfluidic lines, isolators, and lyophilizers; buffer/media prep is scheduled to eliminate hidden bottlenecks. Schedules include buffers that plant managers believe in February. Finance and operations see the same dashboard.

Stability and in-use policies—written from the clinic backward

We publish windows clinics can act on: −80/−20/2–8 °C storage with validated in-use at room temperature and 2–8 °C after first puncture for multi-dose vials (if permitted), freeze–thaw limits, and draw-up/hold rules in ISO 5. For LNPs, size drift limits and potency retention; for emulsions, droplet stability cutoffs; for alum, adsorption integrity; for conjugates, free saccharide growth thresholds. We test the route your couriers will actually drive and the hours your clinics will actually hold. The policy goes into the label without drama.

Case studies (composite, de-identified)

mRNA vaccine with room-temperature clinic simplicity
Need: A two-dose schedule with limited ultra-cold capacity at trial sites.
Approach: Tight IVT control, dsRNA suppression, lipid composition with biodegradable ionizable lipid; LNP twin kept size at 72 ± 3 nm; lyophilized DP with sucrose/trehalose cycle defined by DSC/Tg′; reconstitution ≤20 min, size drift +4 nm, potency ≥0.92×.
Outcome: −20 °C storage, 72-hour 2–8 °C in-use; Module 3 reviewed without CMC-driven questions; enrollment stayed on schedule.

Recombinant VLP with adjuvant discipline
Need: VLP assembly and emulsion adjuvant control for consistent immunogenicity.
Approach: Yeast platform, controlled secretion and glycoform; assembly verified by EM and AUC; emulsion droplet size 140–160 nm with low CV; potency by pseudovirus neutralization.
Outcome: Neutralization titers met targets with tighter error bars; comparability for adjuvant surfactant supplier change executed in six weeks.

Glycoconjugate with free-saccharide control
Need: O-acetylation stability and free saccharide below regulatory expectations.
Approach: Carbohydrate platform controlled chain length and activation; degree of substitution tuned; free saccharide removed by targeted polish; HPAEC-PAD validated.
Outcome: Free saccharide < spec with stability margin; O-acetylation maintained; dossier read cleanly, avoiding late analytical work.

Adenoviral vector with infectivity-first analytics
Need: High infectivity per vg and cold-chain resilience.
Approach: MOI and harvest tuned by off-gas and viability; polishing reduced host DNA; potency in transduction matched antigen expression window; cryo policy written from clinic backward.
Outcome: Infectivity/vg ratio improved 1.5×; fewer clinical cold-chain deviations; rapid agency acceptance of CMC.

RFP checklist

• Show a real QTPP → CQA → CPP map for a vaccine your team filed, plus edge-of-failure data that set CPP ranges.
• Provide one soft-sensor or twin validation report (scope, residual-based alarms, re-qualification cadence) used in LNP or emulsion control.
• Produce the potency suite you validated (neutralization/HAI/OPA/ELISpot) with method lifecycle status and system suitability.
• Share a stability table that lists storage temps, in-use windows, and freeze–thaw limits with acceptance tied to potency and particle/droplet attributes.
• Provide a completed comparability protocol you executed (antigen edit, lipid change, adjuvant supplier) with cycle time and outcome.
• Show an eBR excerpt where FRR/TFR or adjuvant mixing decisions were recorded with reasons and alarms; “operator adjusted” is not documentation.

If a vendor cannot produce those artifacts, they sell hope, not Vaccine CDMO Services.

Engagement model and deliverables

Design-to-Proof (8–12 weeks)

• Risk ledger across modality and route; antigen or sequence architecture; adjuvant/delivery rationale.
• Mini-DoE plans for high-leverage knobs (IVT/dsRNA, LNP FRR/TFR, expression pH/temperature, emulsion mixing).
• Analytics matrix with qualification sequence; draft potency suite matched to mechanism.
• Preliminary stability and in-use policy keyed to trial operations.
• Draft CMC backbone with comparability hooks.

Development-to-IND/IMPD (12–20 weeks)

• Scale-down models, method validation plans, edge-of-failure data, and PPQ/CPV scaffolds.
• Pilot lots with potency, particle or droplet attributes, and dossier-ready analytics.
• Supply plans for lipids/adjuvants/resins/filters with dual-sourcing or safety stocks.
• Draft Module 3 sections and WHO PQ roadmap (if applicable).

GMP and launch

• PPQ with worst-case inside proven ranges; CPV for CQAs and model residuals.
• Lifecycle plans per ICH Q12; comparability protocols ready to execute for expected changes.
• Cold-chain validation, label-ready in-use SOPs, and clinic-proof instructions.

Vaccine CDMO- Top 50 FAQ

1. Do you handle both mRNA and protein-based vaccines?
Yes. Elise supports full mRNA/saRNA vaccine workflows (template-to-LNP) and recombinant subunit or VLP vaccines with adjuvant integration. Conjugate and viral-vector platforms are also supported under GMP.

2. What vaccine platforms can Elise Biopharma manufacture?
mRNA, saRNA, circRNA, DNA, recombinant protein, VLP, glycoconjugate, and viral vectors (AAV, adenoviral, MVA). Each is delivered with its own validated control strategy.

3. Can you take a vaccine from preclinical to GMP?
Yes. We cover design-to-proof, pilot-to-GMP, and PPQ/CPV stages with consistent QMS oversight and validated comparability protocols.

4. How fast can we reach IND or IMPD submission?
Typically 8–12 weeks for design-to-proof and 12–20 weeks to IND/IMPD readiness, depending on potency suite maturity and supply chain complexity.

5. How does Elise control LNP and emulsion variability?
Through digital twins and inline PAT: FRR/TFR/temperature corridors, inline DLS, EM correlation, droplet-size control, and residual-based alarms before QC release.

6. What types of adjuvants do you work with?
Alum, squalene emulsions, saponins, CpG/TLR agonists, liposomal and polymer-based adjuvants—all integrated under validated mixing and adsorption processes.

7. Can Elise prepare WHO prequalification-ready documentation?
Yes. We write to WHO PQ standards, including stability, reference standards, lot-release logic, and cold-chain validation for LMIC distribution.

8. What is your facility biosafety level?
BSL-2 for most vaccines; escalation to BSL-3 partners for high-containment vector or pathogen work.

9. What fill-finish options do you offer?
Aseptic ISO 5 isolators for vials, pre-filled syringes, and cartridges, with nitrogen overlay and 100% in-line weight checks.

10. How is cold-chain storage validated?
With real-time temperature logging, excursion studies, and validated -80 °C, -20 °C, and 2–8 °C storage and shipping SOPs.

11. Do you offer lyophilized vaccine formulations?
Yes. Lyophilization cycles are QbD-engineered with DSC/Tg′ mapping, validated reconstitution (≤+5 nm drift), and potency ≥0.9× fresh.

12. Can Elise validate potency assays beyond ELISA?
Yes. Neutralization (PRNT/pseudovirus), HAI, OPA, and cell-based potency assays with full validation and system suitability are offered.

13. How is vaccine stability tested?
We perform real-time, accelerated, and stress testing (light, agitation, freeze–thaw) per ICH Q1A/Q5C, tied to in-use policies.

14. Can Elise support conjugate vaccine analytics?
Yes. Free saccharide, O-acetylation, and degree of substitution by HPAEC-PAD, HILIC, and LC-MS; conjugation efficiency and potency validated for regulatory submission.

15. What defines Elise’s quality system?
Integrated ALCOA+ digital QMS, full electronic batch records, GMP suites certified under ISO 9001 / 13485, and 21 CFR Part 11 compliance.

16. How are adjuvant batches qualified?
By droplet size, surfactant ratios, zeta potential, pH, and preservative compatibility, with adsorption isotherms confirmed for antigen stability.

17. Do you support combination or multivalent vaccines?
Yes. We design antigen/adjuvant interactions and perform analytical deconvolution for multivalent stability and potency.

18. How do you manage regulatory comparability?
Prewritten ICH Q5E/Q12 protocols for antigen edits, adjuvant changes, and lipid or site moves ensure fast, traceable comparability.

19. Can Elise help design potency reference standards?
Yes. We produce and characterize in-house reference standards for ELISA, neutralization, or OPA, validated for linearity and stability.

20. How are viral-vectored vaccines handled?
BSL-2 production, defined MOI/infection windows, empty/full separation, potency by transduction readouts, and validated cryostability.

21. What particle size and PDI do your LNP vaccines achieve?
Typical ranges: 60–90 nm, PDI ≤ 0.05, and encapsulation ≥90–95%, validated across FRR/TFR and temperature corridors.

22. How do you prevent dsRNA contamination in RNA vaccines?
By controlled IVT kinetics, magnesium balance, selective purification, and orthogonal dsRNA quantitation (J2 ELISA + HPLC or dot-blot).

23. Can you integrate thermostabilization technologies?
Yes. We offer sugar-glass stabilization, polymer matrices, and lyophilized options for room-temperature or 2–8 °C deployment.

24. What are your endotoxin and residual limits?
Endotoxin ≤0.1 EU/mg for proteins, ≤0.01 EU/µg for RNA; residual DNA, protein, and solvent limits aligned with ICH Q6B expectations.

25. Can Elise assist with WHO or CEPI grant compliance?
Yes. We provide CMC documentation, project reporting, and cost modeling aligned with WHO/CEPI audit frameworks.

26. How do you ensure scalability from 2 L to 2,000 L?
By geometric similarity, power-per-volume modeling, oxygen and heat load envelopes, and validated scale-down models before tech transfer.

27. Are vaccine analytics validated to GMP?
Yes. All methods are qualified, validated, and included in method lifecycle management per ICH Q2(R2), with periodic requalification.

28. Do you offer potency bridging for antigen updates?
Yes. Comparability plans include potency bridging (ELISA, neutralization, OPA) with statistical justification and pre-agreed acceptance ranges.

29. How do you control emulsions and particle stability long-term?
By shear mapping, droplet coalescence modeling, antioxidant screening, and container–closure testing under accelerated and real-time conditions.

30. Can Elise Biopharma manage full vaccine CMC authoring?
Yes. We draft Module 3 for mRNA, recombinant, conjugate, and vector vaccines, including QTPP→CQA→CPP maps, PPQ/CPV plans, and global alignment with FDA, EMA, and WHO PQ standards.

31. Can you quantify and control dsRNA species in mRNA/saRNA beyond J2 ELISA?
Yes. We pair J2 ELISA with orthogonal quantitation: (a) ion-pair RP-HPLC with aU detection to resolve long vs short duplexes; (b) dot-blot with calibrated dsRNA ladders; and (c) RNase III/T1 digestion followed by LC to confirm duplex enrichment. During IVT, we map dsRNA formation to Mg²⁺ activity, NTP ratios, and temperature dwell; downstream, AEX polishing (salt/pH windows) and cellulose-based binds are tuned by fraction-level dsRNA measurements. Pooling rules trigger only when both primary and orthogonal assays agree, and acceptance bands are tied to in-vitro innate response (IFN-β/ISG) thresholds—so the number is analytically true and biologically relevant.

32. Do you characterize LNP polymorphism and fusion propensity under shear and excipient stress?
We do. Beyond size/PDI, we evaluate polymorphism via cryo-EM class averages, SAXS for internal ordering, and Laurdan GP for membrane packing. Fusion/aggregation risk is profiled across shear ladders (capillary, needle gauges, peristaltic) and excipient challenges (polysorbates, sugars, buffers) with kinetic DLS and fluorescence dequenching (R18 or calcein). A microfluidic stress rig recreates infusion hardware conditions; acceptable operating envelopes (flow, tubing, temperature) are codified into in-use SOPs. This prevents clinical line-induced size creep and potency loss—common failure modes we de-risk proactively.

33. Can you resolve AAV empty/intermediate/full particles and link the ratio to potency?
Yes. We combine CsCl/iodixanol gradients with AVB-affinity + anion-exchange to quantify empty/intermediate/full, then verify by cryo-EM particle counting. ddPCR (vg), ELISA (capsid), and infectivity (TU) generate a calibrated index of TU/vg that ties particle composition to biological function. Acceptance ranges are justified against potency and dose economics, not cosmetics, so we avoid over-polishing that erodes yield without clinical benefit.

34. How do you engineer alum adsorption without antigen unfolding or epitope masking?
We generate adsorption isotherms vs pH/ionic strength and measure retained structure using DSC/Tm shifts, HDX-MS or peptide mapping for local unfolding, and epitope ELISAs with conformation-sensitive antibodies. Where alum surface chemistry (AIPO₄ vs AIO(OH)) alters presentation, we switch lattice type or co-adsorb stabilizers (histidine, phosphate buffers, sugars) validated not to desorb antigen in-use. Release testing includes desorption challenge and potency to ensure the same antigen that adsorbed is what the immune system sees.

35. Do you provide high-resolution glycan mapping for subunit antigens and link glycoforms to function?
Yes. We run released N-glycan HILIC-UPLC-FLR-MS with exoglycosidase arrays, site-specific glycoproteomics, and, when needed, intact mass/top-down. Functional correlation uses SPR/BLI kinetics and cell-based assays (e.g., FcγR engagement, complement activation). If a glycoform spectrum affects neutralization or Fc-mediated functions, we lock a CQA window and a control strategy (host engineering, feed, temperature, pH) that holds the envelope across scale and sites.

36. Can you execute OPA (opsonophagocytic activity) with statistical power for conjugate vaccines?
Yes. Our OPA uses standardized target strains, complement sources, and phagocyte lots, with inter-run controls and 4-parameter logistic fits. We define LLOQ/ULOQ, parallelism, and precision (inter/intra-assay CV) per ICH. Equivalence margins are pre-specified so lot release and comparability bridge antigen edits or conjugation parameter changes without re-litigating assay performance.

37. Do you model and validate micro-emulsion droplet stability under cold-chain excursions?
We do excursion simulations (−5 → +25 °C cycles) and measure droplet coalescence (DLS, laser diffraction), Ostwald ripening (Stern-Volmer analysis), and surfactant depletion kinetics. Container–closure OTR/MVTR is qualified (headspace oxygen, foil pouches), and antioxidant systems are screened (α-tocopherol, EDTA) for droplet stability without compromising potency. Results define excursion-tolerant labels and handling windows that clinics can actually execute.

38. Can you deliver thermostable (2–8 °C or RT) RNA or protein vaccines via lyophilized formats?
Yes. We design lyophilization cycles (nucleation control, primary/secondary) using DSC/Tg′ and freeze-dry microscopy, select excipient matrices (sucrose/trehalose, histidine, leucine) to prevent fusion/aggregation, and verify reconstitution targets (size drift ≤+5 nm; potency ≥0.9×). For proteins, we map aggregation pathways (SEC-MALS, AUC) and add sugar-amino stabilizers as needed. We then validate in-use stability after reconstitution (2–8 °C, RT) with defined time limits.

39. How do you quantify and limit host-cell DNA/protein in VLPs and subunits to ICH Q6B expectations?
Host DNA is quantified by qPCR with matrix-validated LOD/LOQ and recovery. HCP is measured by platform ELISAs complemented by LC-MS peptide panels to catch antigen-like cross-reactivity. Process trains (AEX/CEX/mixed-mode) are tuned with pH/conductivity ladders that maximize HCP/DNA clearance without harming antigen integrity. CPV trends limits, not just pass/fail, so drift is corrected before it becomes an OOS.

40. Do you support multivalent antigen mapping to prevent antigen–antigen interactions?
Yes. We run forced-mixing studies, DSC/DSF for unfolding interactions, DLS/AUC for hetero-aggregation, and competitive ELISAs to detect epitope interference. Where conflicts arise, we adjust buffer ions, add orthogonal stabilizers, or sequence antigen addition to adjuvants. Multivalent specs carry both per-antigen CQAs and mixture-level stability/potency criteria.

41. Can you tailor LNP composition to tissue tropism and innate-immune footprint?
Yes. We alter ionizable head-group pKa/linkers/branching, helper lipids (DSPC vs DOPE), cholesterol variants, and PEG anchors/chain length to bias liver, LNs, or extrahepatic targets. Innate signature profiling (TLR pathways, cytokines) informs composition; acceptance windows are potency-balanced so reduced reactogenicity does not starve exposure.

42. Do you provide statistical comparability frameworks for antigen sequence edits (e.g., variant updates)?
Yes. We pre-write equivalence protocols with endpoints (potency, neutralization breadth, stability), statistical methods (TOST/equivalence margins), and sample sizes backed by variance history. This enables rapid variant roll-ins without re-validating the entire process.

43. Can you perform high-fidelity empty/full measurement for adenovectors without EM?
We can. We use AEX retention shifts and dye-binding assays correlated to cryo-EM reference lots, plus ddPCR/infectivity ratios. A calibration model (with uncertainty) is maintained and re-qualified per campaign. EM is still used periodically as an anchor.

44. How do you ensure antigen integrity during alum adsorption and fill–finish transfers?
We specify shear budgets (impeller type, rpm, tip speed), nitrogen overlay to limit oxidation, and tubing/needle materials to minimize protein adsorption. Post-mix ELISA/peptide maps and potency verify no epitope loss. Fill lines use laminar profiles and pressure ramps that maintain particle/droplet integrity.

45. Do you integrate cell-mediated immunity (CMI) analytics (ELISpot/ICS) into CMC?
Yes. While CMI is clinical-facing, we integrate ELISpot/ICS panels during development to establish mechanism-consistent potency surrogates. These inform specifications for composition/adjuvant and support comparability when changing antigen or delivery.

46. Can you run AOF (animal-origin-free) conversions and defend them to regulators?
Yes. We migrate media, supplements, and process aids to AOF with a formal risk register, side-by-side comparability (identity, purity, potency, glycoform where relevant), and supplier qualification. The change is filed under ICH Q12 with pre-agreed acceptance criteria.

47. Do you model oxygen/heat envelopes for scale to prevent late-stage failures?
Yes. Scale-down models replicate P/V, tip speed, gas superficial velocity, and back-pressure; digital twins predict OUR/CTR and jacket capacity. We reject setpoints that would be power- or cooling-limited at target scale, then confirm with engineering runs—so limits are real before PPQ.

48. Can you produce and qualify secondary reference standards for potency assays?
Yes. We generate in-house secondary standards characterized vs a primary using orthogonal analytics (ELISA ± neutralization/OPA). We assign unitage via cross-validation, establish stability with ICH storage, and implement bridging rules so assay drift is detectable and correctable.

49. How do you design label and in-use policies that reduce clinic errors?
We link CMC data to practical instructions: thaw durations, allowable pooling times, syringe gauge constraints for LNPs, reconstitution steps, and beyond-use dating at 2–8 °C/RT. Instructions are validated in simulated pharmacy workflows; deviations become CAPAs and label updates.

50. Do you provide full Module 3 authoring and agency-facing CMC support across regions?
Yes. We author M3 for FDA/EMA/PMDA/WHO PQ, align QTPP→CQA→CPP, include PPQ/CPV, and prepare Q&A packages. For PQ, we add supply chain, reference standards, and field-use stability narratives tailored to LMIC constraints. Our team joins meetings to defend the file with data, not adjectives.

Closing thoughts

Vaccine manufacturing is capital in motion and public trust on the line. Programs win when immunology and engineering are bound into one control strategy that regulators can audit and operators can run. Elise Biopharma’s Vaccine CDMO Services are built for that standard: template-to-LNP continuity, subunit and VLP rigor, conjugate specificity, vector discipline, adjuvant recipes that hold, potency suites that matter, and stability and in-use policies written from the clinic backward. Send the target, route, schedule, and constraints; we will return decisions, assays, and dates that hold in the real world.